A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

NCT04414163 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Extranodal NK/T-cell Lymphoma, Nasal Type
Extranodal NK/T-cell Lymphoma

Interventions

DRUG: IMC-001

Sponsor

ImmuneOncia Therapeutics Inc.